Bauer, Sabine and Eigenmann, Jana and Zhao, Yuqi and Fleig, Julia and Hawe, Johann S. and Pan, Calvin and Bongiovanni, Dario and Wengert, Simon and Ma, Angela and Lusis, Aldons J. and Kovacic, Jason C. and Björkegren, Johan L. M. and Maegdefessel, Lars and Schunkert, Heribert and von Scheidt, Moritz (2022) Identification of the Transcription Factor ATF3 as a Direct and Indirect Regulator of the LDLR. Metabolites, 12 (9). p. 840. ISSN 2218-1989
Preview |
Text
Identification-of-the-Transcription-Factor-ATF3-as-a-Direct-and-Indirect-Regulator-of-the-LDLRMetabolites.pdf Available under License Creative Commons Attribution No Derivatives. Download (2MB) | Preview |
Abstract
Coronary artery disease (CAD) is a complex, multifactorial disease caused, in particular, by inflammation and cholesterol metabolism. At the molecular level, the role of tissue-specific signaling pathways leading to CAD is still largely unexplored. This study relied on two main resources: (1) genes with impact on atherosclerosis/CAD, and (2) liver-specific transcriptome analyses from human and mouse studies. The transcription factor activating transcription factor 3 (ATF3) was identified as a key regulator of a liver network relevant to atherosclerosis and linked to inflammation and cholesterol metabolism. ATF3 was predicted to be a direct and indirect (via MAF BZIP Transcription Factor F (MAFF)) regulator of low-density lipoprotein receptor (LDLR). Chromatin immunoprecipitation DNA sequencing (ChIP-seq) data from human liver cells revealed an ATF3 binding motif in the promoter regions of MAFF and LDLR. siRNA knockdown of ATF3 in human Hep3B liver cells significantly upregulated LDLR expression (p < 0.01). Inflammation induced by lipopolysaccharide (LPS) stimulation resulted in significant upregulation of ATF3 (p < 0.01) and subsequent downregulation of LDLR (p < 0.001). Liver-specific expression data from human CAD patients undergoing coronary artery bypass grafting (CABG) surgery (STARNET) and mouse models (HMDP) confirmed the regulatory role of ATF3 in the homeostasis of cholesterol metabolism. This study suggests that ATF3 might be a promising treatment candidate for lowering LDL cholesterol and reducing cardiovascular risk. © 2022 by the authors.
| Item Type: | Article |
|---|---|
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Repository Administrator |
| Date Deposited: | 01 Mar 2023 03:32 |
| Last Modified: | 20 Mar 2023 02:33 |
| URI: | https://eprints.victorchang.edu.au/id/eprint/1298 |
Actions (login required)
 |
View Item |